Disruption of p53 Function Sensitizes Breast Cancer MCF-7 Cells to Cisplatin and Pentoxifylline

Cancer Research

Volumn 55, Issue 8, 1995, Pages 1649-1654

  Fan, Saijun ^a   Smith, Martin L ^a   Rivet, Dennis J ^a   Duba, Diane ^a   Zhan, Qimin ^a   Kohn, Kurt W ^a   Fornace, Albert J ^a   O'Connor, Patrick M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; MESYLIC ACID METHYL ESTER; PENTOXIFYLLINE; PROTEIN P21; PROTEIN P53;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; EXCISION REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WART VIRUS;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL SURVIVAL; CISPLATIN; CLONE CELLS; DOXORUBICIN; ETOPOSIDE; G1 PHASE; GAMMA RAYS; GENES, P53; GENES, VIRAL; HUMAN; METHYL METHANESULFONATE; ONCOGENES; PAPILLOMAVIRUS, HUMAN; PENTOXIFYLLINE; SUPPORT, NON-U.S. GOV'T; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0028901034     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. O'Connor, P. M., and Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin. Cancer Biol., 3: 409–416, 1992.
2. Smith, M. L., and Fornace, Jr., A. J. Genomic instability and the role of p53 mutations in cancer cells. Curr. Opin. Oncol., 7: 69–75, 1995.
3. Hartwell, L. H., and Weinert, T. A. Checkpoints: controls that ensure the order of cell cycle events. Science (Washington DC), 246: 629–634, 1989.
4. Hartwell, L. H., and Kastan, M. B. Cell cycle control and cancer. Science (Washington DC), 266: 1821–1825, 1994.
5. Murray, A. W. Creative blocks: cell-cycle checkpoints and feedback controls. Nature (Lond.), 359: 599–604, 1992.
6. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491–7495, 1992.
7. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 253: 49–52, 1991.
8. Levine, A., Momand, J., and Finlay, C. A. The p53 tumor suppressor gene. Nature (Lond.), 351: 453–456, 1991.
9. Nelson, W. G., and Kastan, M. B. DNA strand breaks: the DNA template alterations that trigger p53 dependent DNA damage response pathways. Mol. Cell. Biol., 14: 1815–1823, 1994.
10. Fan, S., El-Deiry, W. S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Jr., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824–5830, 1994.
11. Lane, D. P. p53: guardian of genome. Nature (Lond.), 358: 15–16, 1992.
12. Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., and Wyllie, A. H. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847–849, 1993.
13. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond.), 362: 849–852, 1993.
14. Lowe, S. W., Ruley, H. E., Jacks, T., and Houseman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957–967, 1993.
15. Radford, I. R., Murphy, J. M., Radley, J. M., and Ellis, S. L. Radiation response of mouse lymphoid and myeloid cell lines. Part II. Apoptotic death is shown by all lines examined. Int. J. Radiat. Biol., 65: 217–227, 1994.
16. O'Connor, P., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776–4780, 1993.
17. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Nad. Acad. Sci. USA, 90: 5742–5746, 1993.
18. Mcllwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718–3722, 1994.
19. Slichenmyer, W. J., Nelson, W. G., Slebos, R. J., and Kastan, M. B. Loss of a p53-associated Gt checkpoint does not decrease cell survival following DNA damage. Cancer Res., 53: 4164–4168, 1993.
20. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in head and neck cancer cell lines. Cancer Res., 53: 3666–3669, 1993.
21. Smith, M. L., Chen, I., Zhan, Q., Bae, I., Chen, C, Gilmer, T., Kastan, M. B., O'Connor, P. M., and Fornace, A. J., Jr. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (Washington DC), 266: 1376–1380, 1994.
22. Zhan, Q., Fan, S., Bae, I., Guillouf, C, Liebermann, D. A., O'Connor, P. M., and Fornace, A. J., Jr. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene, 9: 3743–3751, 1994.
23. Haldar, S., Negrini, N., Monne, M., Sabbinoni, S., and Croce, C. M. Down-regulation of bcl2 by p53 in breast cancer cells. Cancer Res., 54: 2095–2097, 1994.
24. Kessis, T. D., Slebos, R. J., Nelson, W. G., Kastan, M. B., Plunkett, B. S., Han, S. M., Lorincz, A. T., Hedrick, L., and Cho, K. R. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc. Natl. Acad. Sci. USA, 90: 3988–3992, 1993.
25. Ullah, S., Husain, I., Carlton, W., and Sancar, A. Human nucleotide excision repair in vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract. Nucleic Acids Res., 17: 4471–4484, 1989.
26. Sancar, A., and Sancar, G. A. DNA repair enzymes. Annu. Rev. Biochem., 57: 29–67, 1988.
27. Sancar, A. Mechanisms of DNA excision repair. Science (Washington DC), 266: 1954–1956, 1994.
28. Fingert, H. J., Chang, J. D., and Pardee, A. B. Cytotoxic, cell cycle and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res., 46: 2463–2467, 1986.
29. O'Connor, P. M., Ferris, D. K., Pagano, M., Draetta, G., Pines, J., Hunter, T., Longo, D. L., and Kohn, K. W. G2 delay induced by nitrogen mustard in human cells affects cyclin A/Cdk2 and cyclin Bl/Cdc2 kinase complexes differently. J. Biol. Chem., 268: 8298–8308, 1993.
30. Chen, C, and Okayama, H. High efficiency transformation of mammalian cells by Plasmid DNA. Mol. Cell. Biol., 7: 2745–2752, 1987.
31. Smith, M. L., Chen, I. T., Zhan, Q., O'Connor, P. M., and Fornace, A. J., Jr. Involvement of the p53 rumor suppressor in repair of UV-type DNA damage. Oncogene, in press, 1995.
32. Alley, M. C., Scudieco, D. A., Monks, A., et al Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res., 48: 589–601, 1988.
33. Protic, M., Roilides, E., Levine, A. S., and Dixon, K. Enhancement of DNA repair capacity of mammalian cells by carcinogen treatment. Somat. Cell Mol. Genet, 14: 351–357, 1988.
34. Dabholkar, M., Eastman, A., and Reed, E. Host-cell reactivation of cisplatin-damaged pRSVcat in a human lymphoid cell line. Carcinogenesis (Lond.), 11: 1761–1764, 1990.
35. Scheffher, M., Huibregtse, J. M., and Howley, P. M. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc. Natl. Acad. Sci. USA, 91: 8797–8801, 1994.
36. Brown, R., Clugston, C, Burns, P., Edlin, A., Vasey, P., Vojtesek, B., and Kaye, S. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int. J. Cancer, 55: 678–684, 1993.
37. Di Leonardo, A., Linke, S. P., Clarkin, K., and Wahl, G. M. DNA damage triggers a prolonged p53-dependent Gt arrest and long-term induction of Cipl in normal human fibroblasts. Genes Dev., 8: 2540–2551, 1994.
38. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., and Harris, C. C Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA, 91: 2230–2234, 1994.
39. Powell, S. N., DeFrank, J. S., Connell, P., Eogan, M., Preffer, F., Dombkowski, D., Tang, W., and Friend, S. Differential sensitivity of p53- and p53+ cells to caffeine-induced radiosensitization and override of G2 delay. Cancer Res., 55: 1643–1648, 1995.
40. Russell, K. J., Wiens, L. W., Galloway, D. A., and Groudine, M. Abrogation of the G2 checkpoint results in differential radiosensitization of Gj checkpoint-deficient and competent cells. Cancer Res., 55: 1639–1642, 1995.
41. O'Connor, P. M., Ferris, D. K., Hoffmann, I., Jackman, J., Draetta, G., and Kohn, K. W. Role of the cdc25C phosphatase in G2 arrest induced by nitrogen mustard. Proc. Natl. Acad. Sci. USA, 91: 9480–9484, 1994.
42. Fingert, H. J., Pu, A. T., Chen, Z., Googe, P. B., Alley, M. C., and Pardee, A. B. In vivo and in vitro enhanced antitumor effects by pentoxifylline in human cancer cells treated with thiotepa. Cancer Res., 48: 4375–4381, 1988.
43. Rail, T. W. Drugs used in the treatment of asthma. In: A. G. Gilman, T. W. Rail, A. S. Nies, and P. Taylor (eds.), Goodman and Gilman's Pharmacological Basis of Therapeutics, Ed. 8, pp. 618–637. New York: Pergamon Press, 1985.